Paper Details
- Home
- Paper Details
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study.
Author: AkinolaMary, ButlerChris, ChanJane Y C, Davis JonesGabriel, FrangouEleni, GallowayJoanne, GeddesJohn, HallamAngela, HusainMasud, KoychevIvan, LoveSharon, ManoharSanjay G, McShaneRupert, MuraSergio, SenArjune, SymmondsMkael, TaiXin You, ThompsonSian, Van Der PuttRohan
Original Abstract of the Article :
Although Alzheimer's disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licenced treatments only offer modest benefit at best. Seizures, which are more common in patients with Alzheimer's disease than age matched controls, may contribute to the loss of n...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325256/
データ提供：米国国立医学図書館（NLM）
Levetiracetam: A Potential Hope for Alzheimer's Disease Treatment
Alzheimer's disease is a daunting challenge, like a vast desert that robs individuals of their memories and cognitive abilities. This research explores the potential of levetiracetam, an anti-seizure medication, for treating Alzheimer's disease. The study, a double-blind, placebo-controlled, randomized crossover proof-of-concept study, investigated the effects of levetiracetam on memory difficulties in individuals with Alzheimer's disease.
The study draws upon the knowledge that seizures are more common in patients with Alzheimer's disease than age-matched controls. The authors hypothesize that these seizures may contribute to nerve cell loss and disrupt brain function, presenting potential drug targets. Encouraging results from animal models and previous studies exploring levetiracetam's effects on memory difficulties in patients with mild cognitive impairment, a precursor to Alzheimer's disease, led to this investigation.
A Potential New Treatment for Alzheimer's Disease
This study, while still in its early stages, offers a glimmer of hope for Alzheimer's disease treatment. Levetiracetam, already known for its safety and efficacy in treating epilepsy, shows promise in potentially improving memory difficulties in individuals with Alzheimer's disease.
Exploring New Avenues for Alzheimer's Treatment
The ongoing search for effective Alzheimer's treatments requires exploring new and innovative approaches. This research, with its focus on levetiracetam, provides a promising avenue for further investigation and development of treatments that could potentially improve the lives of those affected by this debilitating disease.
Dr. Camel's Conclusion
Alzheimer's disease is a harsh desert, stripping away memories and leaving a trail of devastation. However, this research reminds us that we must continue to explore new paths in the search for effective treatments. Levetiracetam, with its promising potential, could offer a glimmer of hope in the fight against this challenging disease.
Date :
- Date Completed 2021-08-03
- Date Revised 2021-08-06
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.